Chengdu Kanghong Pharmaceuticals Group Co Ltd - Asset Resilience Ratio
Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has an Asset Resilience Ratio of 4.31% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Chengdu Kanghong Pharmaceuticals Group C PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2022)
This chart shows how Chengdu Kanghong Pharmaceuticals Group Co Ltd's Asset Resilience Ratio has changed over time. See how leveraged is Chengdu Kanghong Pharmaceuticals Group C's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Chengdu Kanghong Pharmaceuticals Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Chengdu Kanghong Pharmaceuticals Group C stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥440.00 Million | 4.31% |
| Total Liquid Assets | CN¥440.00 Million | 4.31% |
Asset Resilience Insights
- Limited Liquidity: Chengdu Kanghong Pharmaceuticals Group Co Ltd maintains only 4.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Chengdu Kanghong Pharmaceuticals Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2015–2022)
The table below shows the annual Asset Resilience Ratio data for Chengdu Kanghong Pharmaceuticals Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 1.30% | CN¥100.00 Million ≈ $14.63 Million |
CN¥7.72 Billion ≈ $1.13 Billion |
-1.58pp |
| 2021-12-31 | 2.88% | CN¥200.00 Million ≈ $29.27 Million |
CN¥6.96 Billion ≈ $1.02 Billion |
-1.21pp |
| 2018-12-31 | 4.08% | CN¥212.00 Million ≈ $31.02 Million |
CN¥5.19 Billion ≈ $760.17 Million |
-2.84pp |
| 2016-12-31 | 6.92% | CN¥260.00 Million ≈ $38.05 Million |
CN¥3.76 Billion ≈ $549.94 Million |
-0.32pp |
| 2015-12-31 | 7.24% | CN¥210.00 Million ≈ $30.73 Million |
CN¥2.90 Billion ≈ $424.54 Million |
-- |
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices in China. It develops medicines for ophthalmic, neuropsychiatric, and others. The company was founded in 1996 and is headquartered in Chengdu, China.